Welsh AMD network established

Article

An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales.

An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales.

As of November 20, Lucentis (ranibizumab; Novartis) for the treatment of age-related macular degeneration (AMD) in both eyes has been available on the National Health Service (NHS) in Wales. The availability and reimbursement of Lucentis has exerted increasing pressure on the services available in the country. In response, the government has established the nine-centre hospital-based network, and plans to increase staff levels this month, both to ensure long-term training and expertise in the treatment of AMD and to establish a uniform quality of eye care throughout Wales. Health Minister Edwina Hart has also announced a £15 million (€17.9 million) commitment to fund Lucentis in 2009 and 2010.

Eight of the nine treatment centres in the ophthalmology network are already treating patients. The ninth will be located in Amman Valley Hospital in Ammanford, Carmarthenshire.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.